Additionally, a clinical study reported in the New England Journal of Medicine revealed that first-line treatment with osimertinib-chemotherapy led to significantly longer PFS than osimertinib monotherapy among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).437 These studies mark significant advancements in combination therapies for cancer treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.